FAGR — Fagron NV Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedMid CapHigh Flyer
- €1.20bn
- €1.48bn
- €683.88m
- 80
- 36
- 78
- 73
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.23 | ||
| PEG Ratio (f) | 2.02 | ||
| EPS Growth (f) | 8.15% | ||
| Dividend Yield (f) | 1.7% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.02 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 13.43 | ||
| Price to Sales | 1.79 | ||
| EV to EBITDA | 11.62 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.24% | ||
| Return on Equity | 19.21% | ||
| Operating Margin | 14.32% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 471.68 | 534.7 | 555.97 | 573.81 | 683.88 | 740 | 791.6 | 9.54% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -6.42 | +26.73 | +8.71 | +0.02 | +17.81 | +0.67 | +17.88 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.
Directors
- Koen Hoffman CHM (53)
- Rafael Padilla CEO (42)
- Karin de Jong CFO (41)
- Constantijn van Rietschoten EXB (50)
- Marc Coucke DRC (56)
- Michael Schenck DRC (39)
- Veerle Deprez IND (60)
- Robert ten Hoedt IND (61)
- Giulia Van Waeyenberge IND (39)
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- July 3rd, 2007
- Public Since
- October 5th, 2007
- No. of Employees
- 3,162
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Euronext - Brussels
- Shares in Issue
- 73,125,277
- Address
- Venecoweg 20A, NAZARETH, 9810
- Web
- https://fagron.com/
- Phone
- +32 80012880
- Auditors
- Deloitte Bedrijfsrevisoren
Upcoming Events for FAGR
Q3 2023 Fagron NV Trading Statement Release
Q3 2023 Fagron NV Earnings Release
Similar to FAGR
Bone Therapeutics SA
Euronext - Brussels
Hyloris Pharmaceuticals SA
Euronext - Brussels
Mithra Pharmaceuticals SA
Euronext - Brussels
Financiere de Tubize SA
Euronext - Brussels
UCB SA
Euronext - Brussels
FAQ
What is the Fagron NV share price?
As of Today at 07:07 UTC, shares in Fagron NV are trading at €16.70. This share price information is delayed by 15 minutes.
How has the Fagron NV share price performed this year?
Shares in Fagron NV last closed at €16.70 and the price had moved by +2.02% over the past 365 days. In terms of relative price strength the Fagron NV share price has underperformed the FTSE Global All Cap Index by -3.09% over the past year.
What are the analyst and broker recommendations for Fagron NV?
The overall consensus recommendation for Fagron NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Fagron NV dividend yield?
The Fagron NV dividend yield is 1.05% based on the trailing twelve month period.
Does Fagron NV pay a dividend?
Last year, Fagron NV paid a total dividend of €0.18, and it currently has a trailing dividend yield of 1.05%. We do not have any data on when Fagron NV is to next pay dividends.
When does Fagron NV next pay dividends?
We do not have data on when Fagron NV is to next pay dividends. The historic dividend yield on Fagron NV shares is currently 1.05%.
How do I buy Fagron NV shares?
To buy shares in Fagron NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Fagron NV?
As of the previous close price of €16.70, shares in Fagron NV had a market capitalisation of €1.20bn.
Where are Fagron NV shares listed?
Here are the trading details for Fagron NV:
- Country of listing: Belgium
- Exchange: BRU
- Ticker Symbol: FAGR
What kind of share is Fagron NV?
Based on an overall assessment of its quality, value and momentum Fagron NV is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Fagron NV share price forecast for 2023?
The analyst consensus target price for shares in Fagron NV is €21.03. That is 25.92% above the last closing price of €16.70.
Analysts covering Fagron NV currently have a consensus Earnings Per Share (EPS) forecast of €1.02 for the next financial year.
What is the trend in the Fagron NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fagron NV. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +25.27%.
As of the last closing price of €16.70, shares in Fagron NV were trading +18.09% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Fagron NV PE Ratio?
The Fagron NV PE ratio based on its reported earnings over the past 12 months is 15.23. The shares last closed at €16.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Fagron NV?
Fagron NV's management team is headed by:
- Koen Hoffman - CHM
- Rafael Padilla - CEO
- Karin de Jong - CFO
- Constantijn van Rietschoten - EXB
- Marc Coucke - DRC
- Michael Schenck - DRC
- Veerle Deprez - IND
- Robert ten Hoedt - IND
- Giulia Van Waeyenberge - IND